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Summary Coronary stents have been used for the treatment of patients with coronary artery
disease (CAD), and signiﬁcantly improved procedural safety and are associated with a lower
rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have
been dominant for the treatment of CAD with efﬁcacy in signiﬁcantly reducing both restenosis
and target lesion revascularization. However, late and very late stent thrombosis have become
a major concern in DES-implanted arteries compared with those treated with bare-metal stents
(BMS). This review focuses on the feature of DES thrombosis and pathological examination and
dual antiplatelet therapy for prevention of stent thrombosis.Currently, the incidence of stent thrombosis associated with ﬁrst-generation and second-
generation DES remains unclear in data from real-world cohort registry studies. Further studies
of larger multicenter trials would give us insight into the speciﬁc mechanisms of stent thrombosis
among different generations of DES.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Coronary stents have been used for the treatment of
patients with coronary stenosis, and their procedural safety
and the incidence of restenosis were signiﬁcantly improved
compared with balloon angioplasty alone [1,2]. Coronary
stents prevent acute coronary occlusion, coronary dissec-
tion, and the recoil of the coronary artery after balloon
angioplasty.
Drug-eluting stents (DES) especially reduced the resteno-
sis rate from 30% to 40% with balloon angioplasty alone down
to about 5%.
The use of DES has reduced the rate of target lesion
revascularization (TLR) and by-pass surgery as a treatment
for stent restenosis after stent implantation [3,4]. However,
stent thrombosis in the follow-up period became a new unfa-
vorable issue for patients’ prognosis in this stent era. This
review presents a clinical and pathological overview of this
complication after stent implantation.
Stent thrombosis in clinical studies
Individual reports and meta-analyses of randomized trials
showed no signiﬁcant increase in stent thrombosis risk asso-
ciated with DES compared with bare-metal stents (BMS), at
1 year [5—7].
Wenaweser et al. reported the incidence of stent throm-
bosis associated with DES at 4-year follow-up of a cohort
study. In that study, deﬁnite stent thrombosis occurred in
192 of 8146 patients with an incidence density of 1.0/100
patient-years and a cumulative incidence of 3.3% at 4 years.
The hazard of stent thrombosis continued at a steady rate
of 0.53% [95% conﬁdence interval (CI): 0.44—0.64] between
30 days and 4 years. The use of paclitaxel-eluting stents
(PES) [hazard ratio (HR): 1.67; 95% CI: 1.08—2.56] was an
independent predictor of late stent thrombosis [8].
Stettler et al. reported a meta-analysis of the long-
term outcomes of DES, including second-generation DES.
It showed that mortality was similar with BMS, sirolimus-
eluting stents (SES), and PES. HRs were 1.00 (95% CI
0.82—1.25) for SES versus BMS, 1.03 (0.84—1.22) for PES
versus BMS, and 0.96 (0.83—1.24) for SES versus PES. SES
were associated with the lowest risk of myocardial infarc-
tion (HR 0.81, 95% CI 0.66—0.97, p = 0.030 vs BMS; 0.83,
0.71—1.00, p = 0.045 vs PES). There were no signiﬁcant dif-
ferences in the risk of deﬁnite stent thrombosis (0 days to
4 years). However, the risk of late deﬁnite stent throm-
bosis (>30 days) was increased with PES (HR 2.11, 95% CI
1.19—4.23, p = 0.017 vs BMS; 1.85, 1.02—3.85, p = 0.041 vs
SES). The reduction in TLR seen with DES compared with
BMS was more pronounced with SES than with PES (0.70,
0.56—0.84; p = 0.0021) [9].
Kimura et al. reported the stent thrombosis associ-
ated with SES in a Japanese population. According to this
S
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tbservational study, 2-year outcomes were assessed in
0,778 patients undergoing SES implantation. Incidences
f deﬁnite stent thrombosis were 0.34% at 30 days, 0.54%
t 1 year, and 0.77% at 2 years in the patients with dual
ntiplatelet therapy (DAPT) [10].
The zotarolimus-eluting stent (ZES) (Medtronic Cardio-
ascular, Santa Rosa, CA, USA) combines a more rapid elution
roﬁle of the antiproliferative drug zotarolimus with a thin-
er, more biocompatible phosphorylcholine polymer placed
n a cobalt alloy thin-strut stent. Some follow-up studies
ave indicated that ZES, when compared with BMS, had
n advantageous safety proﬁle and reduced TLR despite a
omewhat higher angiographic late loss than that observed
ith SES and PES [11—13]. However, a biocompatible phos-
horylcholine polymer on a cobalt alloy thin-strut stent has
hown a lower stent thrombosis rate in early results in
umans. In SPIRIT IV, incidences of deﬁnite stent thrombo-
is were 0.34% at 30 days, 0.54% at 1 year, and 0.77% at 2
ears. This result showed the incidence of very late stent
hrombosis that was very low, and ZES is now expected to
ave higher long-term safety for stent thrombosis after stent
eployment [14]. Currently, the PROTECT trial is being con-
ucted to compare the endpoint of rate of stent thrombosis
ith ZES and SES for three years’ follow up.
The everolimus-eluting stent (EES) has been developed
o prevent restenosis after stent low-proﬁle (81m) struts.
herefore, it is currently being used most frequently in
he world. In ENDEAVOR III, 3687 patients were randomly
nrolled at 66 US sites to receive EES or PES. The 1-year
ates of myocardial infarction and stent thrombosis were
igniﬁcantly lower with EES than with PES (1.9% vs. 3.1%,
= 0.02 for myocardial infarction; 0.17% vs. 0.85%, p = 0.004
or stent thrombosis) [15].
tent thrombosis in DES
ES are now able to signiﬁcantly inhibit in-stent neointimal
roliferation which used to be the biggest cause of stent
estenosis in BMS implantation.
DES have been mainly used for coronary intervention.
ndications for DES have been expanded, for example, in left
ain trunk, bifurcation lesions, complex lesions, and multi-
essel disease. Meanwhile, four patients with late stent
hrombosis were ﬁrst reported in the Lancet in 2004 [16].
ince then, it has been well recognized that patients with
ES implantation might die in the follow-up period due to
tent thrombosis.
Five types of drug-eluting stents have been approved by
he Products, Material and Drug Administration in Japan.
ome studies examined whether DES-implanted patients had
ore frequent or later stent thrombosis compared to the
xpected rate of about 1% occurring within 30 days after
he procedure in patients with BMS [17].
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Table 1 Deﬁnition of stent thrombosis according to Academic Research Consortium criteria [22].
Deﬁnite stent thrombosis
Angiographic conﬁrmation of stent thrombosisa
The presence of a thrombusb that originates in the stent or in the segment 5mm proximal or distal to the stent and
presence of at least 1 of the following criteria within a 48-hour time window:
Acute onset of ischemic symptoms at rest
New ischemic electocardiographic changes that suggest acute ischemia
Typical rise and fall in cardiac biomarkers [refer to deﬁnition of spontaneous myocardial infarction (MI)]
Nonocclusive thrombus
Intracoronary thrombus is deﬁned as a (spheric, ovoid, or irregular) noncalciﬁed ﬁlling defect or lucency surrounded by
contrast material (on 3 sides or within a coronary stenosis) seen in multiple projections, or persistence of contrast material
within the lumen, or a visible embolization of intraluminal material downstream.
Occlusive thrombus
Thrombolysis in myocardial infarction (TIMI) 0 or TIMI 1 intrastent or proximal to a stent up to the most adjacent
proximal side branch or main branch (if originates from the side branch).
Pathological conﬁrmation of stent thrombosis
Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following
thrombectomy.
Probable stent thrombosis
Clinical deﬁnition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following
cases:
Any unexplained death within the ﬁrst 30 daysc
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory
of the implanted stent without angiographic conﬁrmation of stent thrombosis and in the absence of any other obvious cause
Possible stent thrombosis
Clinical deﬁnition of possible stent thrombosis is considered to have occurred with any unexplained death from 30 days
after intracoronary stenting until end of trial follow-up.
a The incidental angiographic documentation of stent occlusion in the absence of clinical signs or symptoms is not considered a conﬁrmed
stent thrombosis (silent occlusion).
b Intracoronary thrombus [34].
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mFor studies with ST-elevation MI population, one may conside
probable stent thrombosis.
However, non-uniform deﬁnition of stent thrombosis has
een used in previous studies, which had a limited power
o detect low-frequency events. Furthermore, observational
tudies have reported an increased risk of thrombotic events
n patients with DES after 1 year, suggesting that late
tent thrombosis may contribute to increased late mortality
17—19,10].
Although these stents have reduced rates of restenosis
nd late lumen loss compared with BMS, late thrombo-
is, a life-threatening complication of this technology, has
merged as a major concern [20,21].
eﬁnition of stent thrombosis
he deﬁnition of stent thrombosis has been established by
he general academic research consortium (ARC) [22].
In the ARC deﬁnition, the deﬁnition of stent thrombosis
s classiﬁed into three categories of deﬁnite, probable, and
ossible according to the height of the potential.
Deﬁnite is deﬁned as a blood clot conﬁrmed by
ngiography in addition to clinical or pathological acute
oronary syndrome. Probable is deﬁned when myocar-
ial infarction occurred in the perfusion area of the
tent the target lesion, or unexplained deaths occurred
ithin 30 days after stent placement. Possible is deﬁned
I
I
texclusion of unexplained death within 30 days as evidence of
hen death without proved cause occurred after 30 days
Table 1).
There is a terminology according to the phase: acute
s deﬁned when thrombosis occurred 0—24 h after stent
mplantation; subacute stent thrombosis, from 24 h to 30
ays after stent implantation; late stent thrombosis, from
0 days to 1 year after stent implantation; very late stent
hrombosis, 1 year after stent implantation. Deﬁnite stent
hrombosis classiﬁcation requires angiographic or autopsy
onﬁrmation (Table 1). The categories of probable and pos-
ible stent thrombosis are shown in Table 1.
Stent thrombosis usually follows an extremely rapid clini-
al course and is prone to lead to acute myocardial infarction
nd sudden death. The ARC deﬁnition of stent thrombosis
ight have not only new onset or acute coronary syndrome
ue to stent thrombosis, but also includes unexplained
eath. Therefore, reported cases of stent thrombosis do
ot have homogeneous pathology. However, the rapid clini-
al course makes it difﬁcult to clarify the main pathological
echanism underlying such unfavorable clinical outcomes.ncidence of stent thrombosis
t was originally considered that the main cause of stent
hrombosis might be due to the long duration of thinner
Stent thrombosis and drug-eluting stents
Figure 1 Stent thrombosis (SPIRIT IV trial). Incidence of
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Fdeﬁnite or probable stent thrombosis according to Academic
Research Consortium criteria [15].
neointima after implantation, resulting from eluted drugs
suppressing proliferation of neointima.
However, DES has no different incidence of thrombosis
compared to BMS. Kastrati et al. reported a meta-analysis
about DES and BMS at 5 years follow-up. In this report, in
terms of mortality and prevalence myocardial infarction,
there was no signiﬁcant difference between DES and BMS
[23].
Daemen et al. reported in the Bern/Rotterdam study that
the annual rate of stent thrombosis after DES implantation
as ARC deﬁnite type up to 3 years increased by 0.6% after 30
days at a frequency of 2.9% for a total of three years, com-
pared to BMS implantation [17]. In the subsequent ﬁve years
of follow up, increasing the frequency of stent thrombosis
was still seen after DES implantation as a major problem.
Meanwhile, the J-Cypher Registry performed in Japan
showed that incidence of stent thrombosis as ARC deﬁnite
type was 0.2%/year, and 0.77% in the cumulative two-year
follow-up [10].
The incidence of stent thrombosis is smaller in the
J-Cypher Registry than the Bern/Rotterdam study. This dis-
crepancy might be explained by the difference of race, some
patient characteristics, and interventional procedures. In
particular, stent implantation has been performed under
intravascular ultrasound guidance frequently in Japan. Use
of high-pressure balloons and post-balloon dilatation after
stenting were more frequent in Japan.
There are few data on stent thrombosis with regard to
second-generation DES compared to ﬁrst-generation DES.
According to SPIRIT IV, the incidence of stent thrombosis
with EES (second generation) was signiﬁcantly smaller than
with PES (ﬁrst generation) at 12 months of follow up [15]
(Fig. 1).
The causes of stent thrombosis
It has been suggested that the stent thrombosis resulted
from an insufﬁcient expansion of the stent, fracture of poly-
mers, inﬂammation provoked by the metal itself of the stent
or the polymer, and delayed healing. These factors might
induce platelet aggregation and ﬁbrin deposition inside the
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ES. However, the exact mechanism is still unknown due to
he relatively low frequency of stent thrombosis.
Recently, Nakazawa et al. pointed out that atheroscle-
osis of the neointima after stenting begins early in DES
ompared to BMS. Such neointima, which has the features
f lipid-rich plaque, is actually observed in both BMS and
ES, however, it can be seen in shorter-term after DES stent
mplantation. According to the autopsy ﬁndings of patients
ho died after stent placement, they reported that there
as speciﬁc ﬁbrin deposition and hypersensitivity reaction
round DES struts [24].
The RESTART study, a Japanese registry, examined the
ifference in baseline characteristics of patients with deﬁ-
ite (ARC deﬁnition) cases among the various types of onset
f stent thrombosis, including 611 stent thrombosis in SES
early stent thrombosis 322, late stent thrombosis 105, and
ery late stent thrombosis 184) [25]. In the baseline char-
cteristics, signiﬁcant differences were found among those
ho had early, late, or very late stent thrombosis. Patients
ith insulin-dependent diabetes mellitus and hemodialysis
ad higher odds ratios (OR) for late and very late stent
hrombosis. In addition, strong intimal proliferation and
eep calciﬁcation were also signiﬁcant determinants of late
tent thrombosis. Thus, the mechanism of stent thrombosis
aries for each phase after stent implantation.
echanism of stent thrombosis
he pathological ﬁndings from patients who died of late DES
hrombosis have demonstrated that delayed arterial heal-
ng characterized by incomplete reendothelialization and
ersistence of ﬁbrin is an important underlying substrate
26,3].
Although clinical predictors such as withdrawal of
ntiplatelet therapy are known to play a role in determin-
ng the probability of late stent thrombosis, the speciﬁc
orphometric and histological parameters that signiﬁcantly
orrelate with late thrombosis remain unknown [27,28].
actors of procedure
mong the procedure-related factors, smaller ﬁnal lumen
imensions (stent malapposition and/or underexpansion),
tent length, persistent slow coronary blood ﬂow, place-
ent of multiple stents, positive remodeling, dissections,
eographic miss, and late stent malapposition due to throm-
us resolution appeared to be signiﬁcant determinants for
he development of in-stent thrombosis [29—34].
In addition, stent length, stent underexpansion, and
esidual stenosis have been observed to correlate with an
ncreased risk for DES stent thrombosis [35,36]. These fac-
ors are of great interest because they can be avoided during
ercutaneous coronary intervention.
actors of lesion characteristicseveral patient-related factors have been associated with
he development of in-stent thrombosis, including low
jection fraction, diabetes mellitus, advanced age, and
tenting in the setting of an acute coronary syndrome.
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Even when limited to the patients with DES, primary
tenting in acute myocardial infarction, diabetes melli-
us, renal failure, and low ejection fraction appears to
e associated with an increased risk for stent thrombosis
30,31,35—39]. In particular, the increased risk in patients
ith acute coronary syndrome could be due to delayed heal-
ng and lack of endothelialization.
hrombogenicity of the stent
tent strut thickness and polymer type also play an
mportant role. It has been reported previously that
he nonerodable polymers of the SES provoke chronic
osinophilic inﬁltration within the arterial wall, suggestive
f hypersensitivity reactions [24].
However, the causal relationship between polymer-
nduced inﬂammation and the incidence of late stent
hrombosis has been proven only in a minority of
atients. Detailed analysis of the morphological changes
hows a localized immune response with predominance
f CD45-positive lymphocytes and eosinophils. One possi-
le explanation of these ﬁndings is that hypersensitivity
eaction, which usually has its peak after the complete
elease of the drug, is likely related to the polymer
40].
Drugs loaded on DES may exert a prothrombogenic effect.
irolimus (rapamycin), a macrocyclic lactone, is used on
ES, because it is known to inhibit proliferation of vascular
mooth muscle cells, important factors in the development
f neointima and restenosis [41,42]. On a subcellular level,
apamycin inhibits the mammalian target of rapamycin,
hich is a downstream target of the phosphatidylinositol-3
inase pathway, which in turn is involved in an inhibitory
ashion in the regulation of tissue factor in endothelial
ells and monocytes [43—45]. Paclitaxel is a lipophilic
iterpenoid that binds to the -subunit of the tubulin
eterodimer, promoting tubulin polymerization, cell cycle
rrest, and inhibition of vascular smooth muscle cell migra-
ion and proliferation [46,47]. In addition, paclitaxel is
nown to activate c-Jun NH2-terminal kinase, an impor-
ant mediator of endothelial and monocytic tissue factor
nduction. Consequently, paclitaxel also enhances tissue fac-
or expression and activity in endothelial cells [48—50].
hus, both rapamycin- and paclitaxel-induced tissue factor
xpression may contribute to a prothrombotic environ-
ent after stenting particularly in the acute and subacute
etting.
ngioscopic ﬁndings of neointima in DES after
eployment
ot only autopsy but also clinical imaging studies suggested
hat the primary etiology of stent thrombosis is the lack of
omplete endothelialization over the stent strut [24].
However, the cause of stent thrombosis is considered
o be multifactorial, and other mechanisms in addition to
elayed healing might be important [51].Underlying plaque tissue characteristics is an also impor-
ant factor. Oyabu et al. reported that SES, as compared
ith BMS, was poorly covered by neointima and that it
as accompanied by thrombus especially when there wasT. Takayama et al.
yellow plaque under the stents. Thus, the thrombogenic
otential in DES-implanted lesions may be sustained by
he inhibition of neointima formation over thrombogenic
laques [52].
Higo et al. reported in their study that multivariate
ogistic regression analysis revealed lesion color (=yellow;
R 5.5, 95% CI, 3.0—10, p < 0.001) and neointima coverage
=grade 0 or 1; OR 5.5, 95% CI, 2.4—13, p < 0.001) as inde-
endent contributors for in-stent thrombus formation at 1
ear after DES implantation [53].
ual anti-platelet therapy after stent
eployment
arfarin with aspirin was previously administered for pre-
enting stent thrombosis, but it was associated with serious
leeding complications.
It was demonstrated that using the antiplatelet drugs
spirin and ticlopidine could reduce bleeding complications,
nd also decrease the occurrence of stent thrombosis. As a
esult, using the two types of antiplatelet drugs has been
standard prescription after stenting. Ticlopidine, which
as a potential side effect particularly for liver function,
as gradually unused, and then a newer antiplatelet drug,
lopidogrel is now frequently used with aspirin.
Currently, the US Food and Drug Administration recom-
ends DAPT with aspirin and clopidogrel for more than 12
onths to avoid DES thrombosis. However, some studies
ointed out that DAPT continuation for more than 1 year
fter DES deployment might have no relationship with stent
hrombosis [54]. The terms of administration of DAPT have
een controversial.
onclusion
ith advances in technology, we expect that stent thrombo-
is may be resolved in the future. On the other hand, there
re many patients that have already been implanted with
he ﬁrst-generation DES. It is necessary to ensure the safety
f patients with implanted ﬁrst-generation DES and to fol-
ow up for a long time. Currently, the incidence of stent
hrombosis between ﬁrst-generation and second-generation
ES has been unclear in real-world cohort registry stud-
es [17,55,56]. Further studies of larger multicenter trials
ould give us the insight into speciﬁc mechanisms of stent
hrombosis among different generations of DES.
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